What changes when EGFR is reduced?
A degradation strategy raises questions about the extent and duration of protein reduction, cell context, and downstream biological effects.
Look beyond
the signal.
Our scientific focus is EGFR degradation in oncology. The goal is to investigate a different way of addressing a protein involved in cancer biology.
A target with
biological complexity.
Understanding a target means studying both its role in disease and the consequences of changing it. Therapeutic potential must be evaluated experimentally.
A receptor involved in
growth and survival signals.
EGFR, or epidermal growth factor receptor, is a receptor tyrosine kinase. Its signaling is relevant to normal cells and to some cancers. Altered signaling is a reason researchers study it as a therapeutic target.
General scientific context; it does not define the eligibility of a patient or the efficacy of a Dvant candidate.
Investigating reduction
of the target protein.
Inhibiting a protein’s activity and promoting its degradation are different research strategies. Dvant’s stated focus is EGFR degraders for solid tumors. This is not a claim that a particular clinical outcome has been established.
The illustration is conceptual. It does not specify a compound structure, binding mode, or validated mechanism for DPI-503.
A hypothesis must
earn its next step.
Target engagement, selectivity, biological response, exposure, and safety all matter in drug development. Laboratory or animal findings do not establish safety or benefit in people.
This website publishes no proprietary experimental dataset or clinical efficacy claim.
Mechanism is a starting point.
Evidence is the path.
A convincing drug-development program must connect an effect on the target to meaningful, reproducible observations and an acceptable safety profile.
Can a candidate become a medicine?
A candidate must be evaluated beyond mechanism alone. Exposure, formulation, manufacturing, toxicology, and clinical evidence remain essential considerations.
Progress needs
precise language.
The company’s public focus is not proof of benefit in any individual tumor type. This website does not identify an approved medicine, announce a clinical trial, or provide treatment recommendations.
SCIENTIFIC & STRATEGIC PARTNERSHIPSMove the science
Connect with Dvant Move the science
forward. Together.
Start a nonconfidential conversation with Dvant Pharma.